US 11,912,695 B2
Benzodiazepine derivatives as RSV inhibitors
Kaicheng Zhu, Belmont, MA (US); Kevin McGrath, Brighton, MA (US); Solymar Negretti-Emmanuelli, Watertown, MA (US); Adam Szymaniak, Boston, MA (US); Jianming Yu, Plainsboro, NJ (US); In Jong Kim, Lexington, MA (US); and Yat Sun Or, Waltham, MA (US)
Assigned to Enanta Pharmaceuticals, Inc., Watertown, MA (US)
Filed by ENANTA PHARMACEUTICALS, INC., Watertown, MA (US)
Filed on Jan. 13, 2022, as Appl. No. 17/574,718.
Application 17/574,718 is a continuation of application No. 16/821,290, filed on Mar. 17, 2020, granted, now 11,254,664.
Claims priority of provisional application 62/821,094, filed on Mar. 20, 2019.
Claims priority of provisional application 62/819,915, filed on Mar. 18, 2019.
Prior Publication US 2022/0227746 A1, Jul. 21, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 413/14 (2006.01); A61K 31/5513 (2006.01); A61P 31/14 (2006.01); C07D 417/14 (2006.01); A61K 45/06 (2006.01)
CPC C07D 413/14 (2013.01) [A61P 31/14 (2018.01); C07D 417/14 (2013.01); A61K 31/5513 (2013.01); A61K 45/06 (2013.01)] 20 Claims
 
1. A compound represented by Formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
A is optionally substituted heteroaryl;
n is 0 or 1;
R1 is halogen;
R3 is optionally substituted —C1-C8 alkyl or optionally substituted C3-C8-cycloalkyl; and
R4 and R5 are each hydrogen.